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Aspirin-exacerbated respiratory disease (AERD) is associated with constitutively elevated synthesis of bronchoconstrictor cystein-
yl-leukotrienes, associated with increased expression of leukotriene (LT)C4 synthase and Th2 cytokines and airway eosinophilia.
We examined whether interleukin-13 can increase LTC4 synthase gene transcription and cysteinyl-leukotriene synthesis in
macrophages isolated from resected human lung tissue and whether an NSAID (indomethacin) can trigger further cysteinyl-
leukotriene synthesis in these cells. Overnight culture of human lung macrophages with IL-13 (10ng/mL) increased spontaneous
andionophore-stimulatedproductionofcysteinyl-leukotrienesby42%(P = 0.02)and52%(P = 0.005),respectively,asquantiﬁed
by enzyme immunoassays, but PCR gene transcription assays did not demonstrate an eﬀect on LTC4S mRNA. The addition of
indomethacin (100μM) did not modulate cysteinyl-leukotriene production in either IL-13-treated or untreated macrophages. We
conclude that while IL-13 enhances cysteinyl-leukotriene synthesis in human lung macrophages, it does not replicate the enhanced
LTC4 synthase expression observed in the AERD lung nor confer sensitivity to NSAIDs.
1.Introduction
Aspirin-exacerbated respiratory disease (AERD) is a syn-
drome in which chronic asthma is accompanied by nonaller-
gic hypersensitivity to nonsteroidal anti-inﬂammatory drugs
(NSAIDs), leading to acute bronchoconstriction and exacer-
bationofotherlowerandupperairwaysymptoms[1,2].The
ability of classical NSAIDs to inhibit prostaglandin synthesis
by cyclooxygenase (COX) isozymes, particularly COX-1, is
implicated in these acute exacerbations [3] ,b u ti ti sn o t
known how they activate mast cells, eosinophils, macro-
phages, epithelium, and other cells to release a range of in-
ﬂammatory mediators in susceptible subjects.
Prominent among these mediators are the cysteinyl-
leukotrienes (cys-LTs), which are potent bronchoconstrictor
lipids synthesised by the 5-lipoxygenase (5-LO)/LTC4 syn-
thase pathway [4]. Compared to NSAID-tolerant asthmatics,
AERD patients have chronically elevated production of cys-
LTs, as demonstrated in bronchoalveolar lavage (BAL) ﬂuid,
induced sputum, exhaled breath condensate, and urine [2].
Together with the clinical eﬃcacy of antileukotriene drugs
[5], this suggests a key role of cys-LTs in chronic AERD, even
when NSAIDs are entirely avoided. Exposure to NSAIDs is
postulated to shunt the shared substrate arachidonic acid
from the prostaglandin (cyclooxygenase) pathway to the leu-
kotriene (5-lipoxygenase) pathway, or to reduce production
ofaprostaglandin,putativelyPGE2,thatnormallysuppresses
leukotriene synthesis via an EP receptor mechanism [2],
possibly via phosphorylation of LTC4 synthase [6]. Increased
cys-LT production is prominent in the acute bronchocon-
striction that results, but it is not understood why NSAIDs
triggertheacutesurgeincys-LTlevelsonlyinAERDsubjects.
In 1998, we described with our collaborators a marked
overexpression of LTC4 synthase, the terminal enzyme for
the cellular biosynthesis of the ﬁrst of the cys-LTs, LTC4,i n
the bronchial mucosa of AERD patients [7]. LTC4 synthase
overexpression was also described in nasal polyps from
aspirin-sensitive rhinitic patients [8]. A model for NSAID
sensitivity was proposed in which enhanced expression of
LTC4 synthase in airway macrophages, mast cells, and eos-
inophils provides the enzymatic capacity for constitutive
overproduction of cys-LTs in AERD [7, 9]. Indeed, total2 Journal of Allergy
numbers of LTC4 synthase-positive cells in the bronchial
mucosa correlate strikingly with increased cys-LT levels in
BAL ﬂuid in AERD subjects [7]. Overexpression of LTC4
synthase may also explain why only AERD subjects respond
adversely to NSAID challenge, as suggested by the unique
relationship between bronchial LTC4 synthase and airway
hyperresponsiveness to aspirin challenge [7].
The view that LTC4 synthase overexpression is a central
anomaly in AERD is supported by recent work in LTC4
synthase transgenic mice [10], although the potential mech-
anismsinvolvedremainunclear.LTC4 synthasecanbeupreg-
ulated by cytokines, including interleukin (IL)-3 and IL-5
in maturing eosinophils [11] and IL-4 and IL-13 in human
cord-blood mast cells [12], while TNFα downregulates LTC4
synthase in monocytes [13]. Immunoexpression of IL-5, but
not IL-3 or GMCSF, is increased in AERD biopsies relative
to aspirin-tolerant subjects [7], but there are no studies of
IL-13 in AERD lung. Macrophages from resected human
lung may represent a useful cellular model for AERD as they
are primary cells that express both the 5-LO/LTC4 synthase
and COX biosynthetic pathway enzymes, and also receptors
for IL-13 that mediate increased expression of the CysLT1
receptor [14]. We hypothesised that culture of human
lung macrophages with IL-13 would increase LTC4 synthase
gene transcription and cys-LT synthesis compared to con-
trol macrophages. We also hypothesised that the NSAID,
indomethacin, would trigger a further release of cys-LTs only
in the IL-13-treated cells.
2. Methods
2.1. Materials. RNALater and the DNA Mastermix were
purchased from Ambion (Warrington, UK). TaqMan Uni-
versal Master Mix, β-actinandLTC4Sgeneexpressionassays,
and MicroAmp optical adhesive ﬁlm were purchased from
Applied Biosystems (Warrington, UK). The ImProm-II re-
verse transcription system was purchased from Promega
(Southampton, UK). The cysteinyl-leukotriene enzyme im-
munoassay (EIA) kit was from Cayman Chemical Europe
(Tallinn, Estonia). TRIzol was purchased from Invitrogen
(Paisley, UK). Recombinant human IL-13 was purchased
from PeproTech (London, UK). Calcium ionophore cal-
cimycin (A23187), indomethacin, Trypan Blue solution
(0.4%), and dimethylsulphoxide (DMSO) were from Sigma
Chemical Company (Poole, UK).
2.2.IsolationandCultureofHumanLungMacrophages. Sam-
ples of lung tissue (wet weight 1.8–35.2g) were collected
from male and female patients undergoing bullectomy or
lobectomy for lung cancer at the Southampton General Hos-
pital, in accordance with ethical approval (08/HO502/32)
fromtheSouthamptonandSouth-WestHampshireResearch
Ethics Committee. None had a history of asthma, but all
were current or exsmokers. Tissue samples were dissected
into 3mm fragments and suspended in Dulbecco’s phos-
phate-buﬀered saline (PBS) containing 0.1M NaCl, 2.7mM
KCl, 1.8mM KH2PO4,a n d1 0 m MN a 2PO4 (pH 7.4).
The suspension was centrifuged (80×g, 20◦C) for 5min,
the supernatant was discarded, and the pellet was resus-
pended in 30mL of lysis buﬀer (155mM NH4Cl, 10mM
KHCO3,0 . 1 m ME D T A ;p H7 . 4 ) .A f t e r5 m i na tr o o m
temperature, the suspension was ﬁltered (70μmﬁ l t e r )a n d
centrifuged (80×g,20◦C, 5min) to remove erythrocyte frag-
ments and other debris. The pellet was resuspended in RPMI
medium supplemented with antibiotics (penicillin 55U/mL,
streptomycin 5mg/mL, and gentamycin 10mg/mL). The
resulting cell population was >90% pure macrophages by
morphology and had viability >90% as determined by exclu-
sion of Trypan Blue dye. Macrophage aliquots were cultured
in RPMI (0.5 × 106 cells/mL) at 37◦C for 16h overnight
with or without IL-13 (10ng/mL) in a 5% CO2 humidiﬁed
atmosphere.
For cys-LT assays, IL-13-treated and untreated cells were
incubated for a further 30min in fresh RPMI medium (0.5×
106 c e l l si n1 m L )i na3 7 ◦C water bath with no addition
(control), with indomethacin (100μM), with calcimycin
(A23187, 1μM), or with both indomethacin and A23187 at
the same concentrations. Calcimycin (A23187) is a calcium
ionophore that liberates arachidonic acid from membrane
phospholipids and activates 5-LO to initiate leukotriene
synthesis. Indomethacin is a classical NSAID which inhibits
both COX-1 and COX-2 at the concentration used. These
reagentsweredilutedfromstocksolutionsindimethylsulfox-
ide (DMSO) such that ﬁnal DMSO concentration in the cell
incubations was always <0.2%. At the end of the incubation,
t u b e sw e r er e m o v e do n t oi c ea n dc e n t r i f u g e d( 2 4 0×g, 4◦C)
for 5 minutes to pellet the cells for RNA analyses. The
supernatants were treated with two volumes of ethanol to
precipitate protein, which was removed by centrifugation.
Ethanolic supernatants were then evaporated to dryness in
vacuo in a GyroVap rotary evaporator and stored at −20◦C
before cys-LT immunoassays.
2.3.RT-qPCRAssayforLTC4S. ForLTC4Sgenetranscription
assays,aliquots(10×106 cells)ofIL-13-treatedanduntreated
cellpelletsweremixedwith0.5mLRNALaterandkeptat4◦C
for 24h, then stored at −20◦C before RNA extraction and
reverse-transcriptase quantitative polymerase chain reaction
(RT-qPCR) assays for LTC4S and beta-actin mRNAs. Macro-
phageswerethawed,vortexed,andtransferredintoRNA-free
Eppendorf tubes. PBS (1mL) was added, and Eppendorfs
were vortexed and centrifuged (2800×g, 20◦C) for 5min
to decrease the viscosity of the RNALater and allow the
macrophages to form a pellet. RNALater was then removed
and the RNA extracted using TRIzol (Invitrogen, Paisley,
UK) by the manufacturer’s protocol. Residual genomic DNA
was digested using Ambion DNA-free (Applied Biosystems,
Warrington, UK). For each RNA sample, the A260/A280
ratio measured by spectrophotometry (Nanodrop ND1000,
ThermoFisher Hemel Hempstead, UK) was >1.8, indicating
an adequate level of purity, and RNA was stored at −80◦C.
To generate cDNA, 1 μg of RNA was reverse transcribed
(Improm-II RT system, Promega, Southampton, UK) using
random hexamer primers and stored at −20◦C.
RT-qPCR was performed on the Lightcycler 480 (Roche
Diagnostics, UK) in 384-well reaction plates using ∼100ng
of template cDNA in quadruplicate 20μL reactions usingJournal of Allergy 3
TaqMan gene expression assays for LTC4S (Hs00168529 m1)
withACTB(beta-actin,Hs99999903 m1)asareferencegene,
both using FAM-labelled hydrolysis probes and TaqMan
universal mastermix II for 40 cycles, as in the manufacturer’s
protocol (Applied Biosystems). Gene expression relative to
ACTB was calculated using the 2−ΔΔCq method. Paired
statistical comparison between IL-13-treated and untreated
cells from n = 12 donors was performed by Wilcoxon signed
rank test for nonparametric data.
2.4. Cysteinyl-Leukotriene Immunoassays. Evaporated super-
natants from 30 min incubations of IL-13-treated and un-
treated macrophages with and without indomethacin and
calcimycin were resuspended in appropriate volumes of PBS
buﬀer and aliquots taken in duplicate for EIA quantiﬁcation
of released cys-LTs. The total cys-LT EIA kits (Cayman
Europe) use a monoclonal primary antibody with 100%
speciﬁcity for LTC4 and LTD4 and 79% speciﬁcity for LTE4.
Cross-reactivitytoLTB4,variousHETEs, andarachidonate is
lessthan4%andtheassayhashighsensitivity(34pg/mL)for
cys-LTs. The assay is based on competition with a standard
LTC4-acetylcholinesterace tracer with Ellman’s reagent as
substrate. Cys-LTs were assayed in duplicate, and concen-
trations are expressed as nanograms of LTC4 released per
million viable macrophages. Data are presented as mean ±
SEM for n = 8 tissue donors, and comparisons between
meanvaluesweremadebytwo-tailedpairedStudent’st-tests,
with P<0.05 considered signiﬁcant.
3. Results
For LTC4S gene transcription assays, human lung macro-
phages from 12 donors (9 male, three female; mean age 64
years, range 49–78 years) were cultured overnight for 16
hours with or without IL-13 (10ng/mL). LTC4S mRNA ex-
pression in each cell sample was detected in quadruplicate
using RT-qPCR, with β-actin as the housekeeping gene. The
mean expression of LTC4S mRNA at 16 hours was not signif-
icantly diﬀerent in IL-13-treated macrophages compared to
their untreated cells (mean log ΔΔCq value = 0.49, P = 0.33,
n = 12)(Figure 1).Thecomparisonremainednonsigniﬁcant
when the single outlying value, caused by an anomalously
low control (β-actin) value in the untreated cells from one
donor, which was not apparent in the IL-13-treated cells
from the same donor, was excluded from the analysis.
Following 16-hour cultures with or without IL-13, ma-
crophages from representative donors (8 males, mean age
67 years, range 56–76) underwent 30-minute incubations
for detection of total cys-LT release (Figure 2). IL-13 pre-
treatment signiﬁcantly increased spontaneous cys-LT release
from 544 ± 215pg/million cells to 825 ± 292pg/million cells
(P = 0.02), a mean increase of 52 ± 17%. Incubation with
indomethacin (100μM) did not signiﬁcantly change cys-LT
release when compared with spontaneous release in either
IL-13-treated or untreated cells (P>0.05).
As expected, the calcium ionophore A23187 (calcimycin,
1μM) boosted the mean release of total cys-LTs by
about 10-fold compared with spontaneous release. Mean
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Figure 1: RT-qPCR assay data for LTC4S mRNA in macrophages
from 12 lung tissue donors after 16 hours of culture in the presence
a n da b s e n c eo f1 0n g / m LI L - 1 3 .V a l u e sa r en o rm a l i s e dt ot h eh o u s e -
keeping gene (β-actin), with ΔCq values representing the number
of doubling cycles taken to reach the threshold, and plotted on
an inverted logarithmic y-axis (as −ΔCq) so that an increase in
LTC4S mRNA is shown as a higher value on the axis. The mean log
change in −ΔCq value was 0.49, representing no signiﬁcant change
in LTC4S mRNA with IL-13 culture (P = 0.3).
release of total cys-LTs after 30min of A23187 stimulation
was signiﬁcantly greater in IL-13-treated cells (7770 ±
630pg/million cells) than in cells not treated with IL-13
(5480 ± 670pg/million cells) (P = 0.005), a mean increase
of 42 ± 10% (Figure 2). Coincubation of indomethacin
(100μM)andA23187(1μM)howeverdidnotshowdiﬀerent
values for cys-LT release compared with A23187 alone in
either IL-13 pretreated or untreated cells.
4. Discussion
Interleukin (IL)-13 is a Th2 cytokine with well-established
roles in promoting airway responsiveness, mucus secretion,
and chemokine production in the allergic lung, acting
principally via a receptor shared with IL-4 and leading to
phosphorylation of the transcription factor STAT6 [15]. IL-
4 can powerfully upregulate LTC4 synthase expression and
activityinhumancord-bloodmastcells[12],whileIL-13can
upregulate the principal receptor for cysteinyl-leukotrienes,
CysLT1R, on human airway smooth muscle cells [16]a n do n
macrophages [14]. This suggested that increased IL-4/IL-13
activitymayberesponsibleforupregulatingtissueexpression
of LTC4 synthase, as observed in the upper and lower airways
in AERD patients [7, 8], and for enhancing responsiveness to
cys-LTs by increasing the expression of CysLT1 receptors, as
described in AERD nasal biopsies [17].4 Journal of Allergy
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Figure 2: Enzyme immunoassay data on release of total cysteinyl-
leukotrienes (cys-LT, pg/million cells) by macrophages from eight
lung tissue donors after culture for 16 hours in the absence or
presence of IL-13 (10ng/mL). Macrophages were then washed and
resuspended in fresh medium for a 30 min incubation with no
further addition (Cont), with the NSAID indomethacin (Indo,
100μM), with the calcium ionophore calcimycin (A23187, 1μM),
or with both indomethacin and calcimycin (Indo + A23187).
Pretreatment with IL-13 signiﬁcantly increased spontaneous cys-LT
release (P = 0.02) and that induced by calcimycin (P = 0.005),
but neither was aﬀected by indomethacin in either IL-13 treated or
untreated cells.
This study therefore explored whether IL-13 can up-
regulate LTC4 synthase transcriptional expression in macro-
phages isolated from resected human lung and whether it
leads to a higher release of cys-LTs, either spontaneously or
in response to a calcium ionophore, compared with macro-
phages not cultured with IL-13. Taqman gene expression
assays failed to show signiﬁcant changes in LTC4S mRNA,
standardised to the beta-actin housekeeping gene (ACTB),
in IL-13 cultures of macrophages from twelve lung tissue
donors (Figure 1). Increases in LTC4S mRNA are detectable
after six hours of IL-4 treatment in human mast cells derived
from cord blood mononuclear cells, and maximal at 24 to
120 hours [12], suggesting that the 16-hour culture with
IL-13 employed in our experiments was reasonable. IL-13
may be less potent on myeloid cells than IL-4, and our cells
were mature lung macrophages from mainly elderly subjects
undergoing lobectomy or bullectomy; these cells may not be
as responsive to IL-13 or other stimuli as cord-blood-derived
mononuclear cells from healthy neonates.
Despite the lack of eﬀect on LTC4S transcription, cul-
ture of lung macrophages with IL-13 did cause signiﬁcant
increases in cys-LT release, an eﬀect that was apparent both
on the low levels of spontaneous cys-LT production in
unstimulated cells and on the tenfold higher levels of cys-LT
release measured in cells stimulated with calcimycin A23187
(Figure 2). Calcimycin acts as a receptor-independent trig-
ger of arachidonate release from membrane phospholipids;
ahighturnoverofsubstratethroughthe5-LO/LTC4 synthase
pathway was intended to simulate rate-limiting conditions,
such that an increase in LTC4 synthase enzyme expression
induced by IL-13 could be revealed by a raised ceiling of cys-
LT synthesis. In the event, the lack of upregulation of LTC4S
mRNA suggests either a nontranscriptional eﬀect of IL-13
or an action on other components of the pathway, possibly
on 5-LO activating protein (FLAP), which is inducible by
cytokines and increases markedly during human alveolar
macrophage maturation [18]. The increases in cys-LT release
seen in the IL-13-cultured macrophages were relatively
modest (42–52%), but suggest that IL-13 could contribute to
increased cys-LT releasability in macrophages in the allergic
asthmatic or AERD lung.
NSAIDs such as indomethacin are proposed to cause
acute AERD reactions by shunting of arachidonate from the
inhibited COX pathway to the 5-LO/LTC4 synthase pathway
or by suppressing synthesis of an inhibitory prostanoid such
as PGE2, thus enhancing cys-LT production [6]. Although
isolated anomalies in COX isozyme expression, prostanoid
synthesis, and EP receptor signalling have been described in
AERD cells and tissues [19, 20], a coherent picture of a sys-
temic prostanoid defect in AERD has yet to emerge [2]. Hu-
man alveolar macrophages constitutively express COX-1 and
synthesise PGE2 [21]. We postulated that endogenous COX
pathwaysinhumanlungmacrophagesmaythereforeprovide
an adequate target for NSAID action, resulting in enhanced
cys-LT release if the 5-LO/LTC4 synthase pathway has
previously been induced by IL-13. No eﬀect of indomethacin
was observed however on either spontaneous or A23187-
stimulated cys-LT release in either IL-13-treated or untreated
cells (Figure 2). In the absence of an eﬀect of IL-13 on LTC4S
mRNA levels, it is not possible to reject our hypothesis that
LTC4 synthase overexpression in a single cell type could
provideasimple cellularmodel ofthekeyfunctionalchanges
within the AERD lung. In vivo, intercellular interactions
may be required, possibly with PGE2 derived from airway
epithelial cells [22] or it may depend on the recruitment of
new populations of LTC4-synthase-expressing cells, such as
eosinophils. It is nevertheless intriguing that human mast
cells derived in culture from the blood mononuclear cells
of AERD subjects show an intrinsically raised capacity for
cys-LT synthesis and that this is suppressed by PGE2 [23],
suggesting that the AERD paradigm can be detected at the
level of a single cell type and that it persists in prolonged cell
culture. Further comparative studies are required in primary
lung cell populations from normal and AERD subjects.
The key features of AERD have recently been replicat-
ed in ovalbumin-sensitised LTC4 synthase transgenic mice
(LTC4S-Tg), including its overexpression in airway macro-
phagesandotherleukocytes,leadingtoincreasedcys-LTsyn-
thesis both before and after NSAID challenge, accompanied
by dramatically increased Th2 cytokines, including IL-13
[10].ThismodelsuggeststhatprimarydysregulationofLTC4
synthase in resident lung cells including macrophages may
initiate overproduction of cys-LTs in patients with AERD.
The cys-LTS may then promote the secondary synthesis
of IL-4, IL-5, and IL-13 from lymphocytes [10] and eosin-
ophils [24], leading to myocyte CysLT1R expression [16],Journal of Allergy 5
suppression of epithelial PGE2 synthesis and EP2 expression
[22], and further induction of LTC4 synthase [11]. While the
LTC4S −444A/C promoter polymorphism [25] has been dis-
counted as an aetiological factor in most AERD populations
[26], other genetic, immunological, and microbial factors
that could directly dysregulate LTC4 synthase in human lung
cells merit further investigation.
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